Cargando…

MicroRNAs in B-cells: from normal differentiation to treatment of malignancies

MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformat...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Sara Correia, Laursen, Maria Bach, Bødker, Julie Støve, Kjeldsen, Malene Krag, Falgreen, Steffen, Schmitz, Alexander, Bøgsted, Martin, Johnsen, Hans Erik, Dybkaer, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381575/
https://www.ncbi.nlm.nih.gov/pubmed/25622103
_version_ 1782364474888421376
author Marques, Sara Correia
Laursen, Maria Bach
Bødker, Julie Støve
Kjeldsen, Malene Krag
Falgreen, Steffen
Schmitz, Alexander
Bøgsted, Martin
Johnsen, Hans Erik
Dybkaer, Karen
author_facet Marques, Sara Correia
Laursen, Maria Bach
Bødker, Julie Støve
Kjeldsen, Malene Krag
Falgreen, Steffen
Schmitz, Alexander
Bøgsted, Martin
Johnsen, Hans Erik
Dybkaer, Karen
author_sort Marques, Sara Correia
collection PubMed
description MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformation due to their function as oncogenes or tumor suppressors. We know that miRNAs are involved in the development of normal B-cells and that different B-cell subsets express specific miRNA profiles according to their degree of differentiation. B-cell-derived malignancies contain transcription signatures reminiscent of their cell of origin. Therefore, we believe that normal and malignant B-cells share features of regulatory networks controlling differentiation and the ability to respond to treatment. The involvement of miRNAs in these processes makes them good biomarker candidates. B-cell malignancies are highly prevalent, and the poor overall survival of patients with these malignancies demands an improvement in stratification according to prognosis and therapy response, wherein we believe miRNAs may be of great importance. We have critically reviewed the literature, and here we sum up the findings of miRNA studies in hematological cancers, from the development and progression of the disease to the response to treatment, with a particular emphasis on B-cell malignancies.
format Online
Article
Text
id pubmed-4381575
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-43815752015-04-09 MicroRNAs in B-cells: from normal differentiation to treatment of malignancies Marques, Sara Correia Laursen, Maria Bach Bødker, Julie Støve Kjeldsen, Malene Krag Falgreen, Steffen Schmitz, Alexander Bøgsted, Martin Johnsen, Hans Erik Dybkaer, Karen Oncotarget Review MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformation due to their function as oncogenes or tumor suppressors. We know that miRNAs are involved in the development of normal B-cells and that different B-cell subsets express specific miRNA profiles according to their degree of differentiation. B-cell-derived malignancies contain transcription signatures reminiscent of their cell of origin. Therefore, we believe that normal and malignant B-cells share features of regulatory networks controlling differentiation and the ability to respond to treatment. The involvement of miRNAs in these processes makes them good biomarker candidates. B-cell malignancies are highly prevalent, and the poor overall survival of patients with these malignancies demands an improvement in stratification according to prognosis and therapy response, wherein we believe miRNAs may be of great importance. We have critically reviewed the literature, and here we sum up the findings of miRNA studies in hematological cancers, from the development and progression of the disease to the response to treatment, with a particular emphasis on B-cell malignancies. Impact Journals LLC 2014-12-10 /pmc/articles/PMC4381575/ /pubmed/25622103 Text en Copyright: © 2015 Marques et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Marques, Sara Correia
Laursen, Maria Bach
Bødker, Julie Støve
Kjeldsen, Malene Krag
Falgreen, Steffen
Schmitz, Alexander
Bøgsted, Martin
Johnsen, Hans Erik
Dybkaer, Karen
MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title_full MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title_fullStr MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title_full_unstemmed MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title_short MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
title_sort micrornas in b-cells: from normal differentiation to treatment of malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381575/
https://www.ncbi.nlm.nih.gov/pubmed/25622103
work_keys_str_mv AT marquessaracorreia micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT laursenmariabach micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT bødkerjuliestøve micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT kjeldsenmalenekrag micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT falgreensteffen micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT schmitzalexander micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT bøgstedmartin micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT johnsenhanserik micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies
AT dybkaerkaren micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies